Reviva Pharmaceuticals Holdings, Inc. Prepaid Expense and Other Assets, Current
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Prepaid Expense and Other Assets, Current of $400.91 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-12
- 2026-06-30: Prepaid Expense and Other Assets, Current $400.91K.
- 2026-03-31: Prepaid Expense and Other Assets, Current $549.68K.
- 2025-12-31: Prepaid Expense and Other Assets, Current $664.68K.
- 2025-09-30: Prepaid Expense and Other Assets, Current $247.93K.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $400.91K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $549.68K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $664.68K 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $247.93K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $346.96K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $756.07K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $666.43K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $325.81K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $525.83K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $743.38K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $254.64K 10-K · filed 2025-04-03 | $332.93K 10-K · filed 2024-04-15 |
| 2023-09-30 | $414.74K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $690.44K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $1.65M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $403.82K 10-K · filed 2024-04-15 | |
| 2022-09-30 | $849.02K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.22M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $1.85M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $1.72M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $402.32K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $733.93K 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $1.01M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $1.82K 10-K · filed 2022-03-15 | |
| 2020-11-30 | $7.62K 10-Q · filed 2021-01-14 | |
| 2020-08-31 | $22.57K 10-Q · filed 2020-10-14 | |
| 2020-05-31 | $41.71K 10-Q · filed 2020-07-07 | |
| 2020-02-29 | $69.58K 10-Q · filed 2021-01-14 | |
| 2019-11-30 | $15.66K 10-Q · filed 2020-01-10 | |
| 2019-08-31 | $38.57K 10-Q · filed 2019-10-08 | |
| 2019-05-31 | $63.99K 10-Q · filed 2019-07-03 | |
| 2019-02-28 | $91.13K 10-K · filed 2020-05-04 | |
| 2018-11-30 | $60.55K 10-Q · filed 2019-01-09 | |
| 2018-08-31 | $78.20K 10-Q · filed 2018-10-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |